Annual Securities Report

Overview

The report describes TMS as a single-segment drug-development biotechnology company focused on advancing its pipeline and building future pharmaceutical products. For the year ended February 29, 2024, it reported ¥607,728 thousand in R&D expenses, with 13 employees engaged in research and development. Its sustainability section covers governance, strategy, risk management, and human-resource development, but states that no quantitative indicators or targets had yet been set for human-resource and internal-environmental policies.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: 1 March 2023 – 29 February 2024
Publication date: 29 May 2024
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services